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Abstract: The mitochondrion is a dynamic eukaryotic organelle that controls lethal and vital functions of
the cell. Being a critical center of metabolic activities and involved in many diseases, mitochondria have
been attracting attention as a potential target for therapeutics, especially for cancer treatment. Structural
and functional differences between healthy and cancerous mitochondria, such as membrane potential,
respiratory rate, energy production pathway, and gene mutations, could be employed for the design of
selective targeting systems for cancer mitochondria. A number of mitochondria-targeting compounds,
including mitochondria-directed conventional drugs, mitochondrial proteins/metabolism-inhibiting
agents, and mitochondria-targeted photosensitizers, have been discussed. Recently, certain drug-free
approaches have been introduced as an alternative to induce selective cancer mitochondria dysfunction,
such as intramitochondrial aggregation, self-assembly, and biomineralization. In this review, we discuss
the recent progress in mitochondria-targeted cancer therapy from the conventional approach of
drug/cytotoxic agent conjugates to advanced drug-free approaches.
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1. Introduction
The mitochondrion is probably the most studied eukaryotic cellular subcompartment due to
its indispensable role in the regulation of cellular metabolism and multifaceted functions associated
with various diseases, such as cancer, neurodegenerative diseases, and diabetes [1–3]. Even though
each cellular compartment is significant, the mitochondrion is an all-rounder carrying multiple
responsibilities including apoptosis (intrinsic) regulation, energy production, respiratory cycle, amino
acid metabolism, and redox signaling [4–6]. On the one hand, mitochondrion produces ATP (adenosine
triphosphate) for cell survival, while, on the other hand, controlling lethal functions, such as apoptosis
and necrosis [7,8]. Lethal functions are mainly regulated by a process called mitochondrial outer
membrane permeation (MOMP) [9], which occurs during an apoptotic trigger, mediated by the
pore-forming activity of proapoptotic proteins, such as the Bcl-2 (B-Cell lymphoma 2) proteins, Bax (Bcl-2
associated X protein), and Bak (Bcl-2 antagonist/killer protein). Mitochondria are critically involved
in the initiation of necrotic cell death as well as in events such as abnormal production of reactive
oxygen species (ROS), mitochondrial swelling, ATP depletion, and failure of Ca2+ homeostasis [10,11].
Mitochondria are key regulators of Ca2+ signaling by taking up and releasing Ca2+ ions. The increase
in the concentration of Ca2+ ions in the mitochondrial matrix activates mitochondrial dehydrogenase
to stimulate oxidative phosphorylation, and Ca2+ ion elevation in the intermembrane space stimulates
the uptake of substrates for oxidative phosphorylation [12,13]. Since mitochondria are critical for
cellular survival and cell cycle maintenance, they have attracted much attention from biologists and
chemists for the past several years.
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Mitochondria-Targeted Cancer Therapeutics
In healthy cells, mitochondria execute a controlled regulation of multiple functions to maintain the
cellular growth–death cycle. However, in the case of tumor cells, to meet the higher metabolic demand
of rapidly proliferating cells, dysregulation of mitochondrial metabolism occurs [14,15]. The difference
between cancer cell mitochondria and normal cells includes several functional alterations, such as
mutation of mtDNA that lead to OXPHOS (oxidative phosphorylation) inhibition and thus deficient
respiration and ATP generation, mutation of mtDNA-encoded mitochondrial enzymes, such as
SDH (succinate dehydrogenase), IDH1 (isocitrate dehydrogenase 1), IDH2 (isocitrate dehydrogenase
2) [16], and structural differences, such as higher membrane potential of cancer cell mitochondria
and higher basicity inside the mitochondrial lumen. The evasion of cell death or inhibition of
mitochondria-mediated apoptosis is a hallmark for cancer. Mitochondria generate ROS, which is
necessary for signaling under normal conditions. However, when apoptosis is inhibited in the case
of cancer, ROS contributes to the neoplastic transformation. Furthermore, for supporting tumor cell
survival under harsh tumorigenic conditions, such as nutrient depletion and hypoxia, mitochondria
provide flexibility in several pathways either by up- or downregulation [17]. This altered mitochondrial
metabolism of cancer cells compared with that of their normal counterparts is advantageous for the
selective targeting of cancer mitochondria in therapeutics, which focuses on the cancer mitochondria
specific features [18]. Directing the therapeutic agent to the mitochondria is an efficient way of
eliminating cancer cells because the designed drug molecules could act at the central point of the cell,
and therefore, engineering mitochondrial-targeted therapeutic agents have gained much interest in
cancer therapy.
Anticancer drugs that selectively disrupt cancerous mitochondria could be achieved by designing
molecules that act on the malignant mitochondria by, for instance, inhibiting glycolysis, depolarizing the
membrane potential, and inhibiting the mitochondrial permeability transition pore [19,20]. However,
penetrating the double-layered membrane of mitochondria requires overcoming certain barriers.
The mitochondria membrane consists of a porous outer membrane and a protein-rich inner membrane,
which are designed for the tight regulation of its metabolism and to prevent foreign substances from
crossing the membrane [21]. To traverse the membrane, the molecules are required to overcome
the activation energy associated with the removal of associated water molecules. Molecules with
delocalized positive charge can lower this activation energy, which allows them to penetrate the
membrane and enter the mitochondria efficiently [22]. The hyperpolarized mitochondrial membrane
of cancer cells (−220 mV) compared with that of healthy mitochondria (−160 mV) facilitates the
fast and selective entry of positively charged molecules specifically to the cancer mitochondria [23].
The most studied example of such cations is the triphenylphosphonium ion (TPP), which is widely
used as a mitochondria-targeting vector. TPP possesses a single positive charge delocalized over the
three phenyl groups and stabilized by resonance. Not only the charge but also the hydrophobicity
associated with this lipophilic cation favor its interaction with the hydrophobic inner mitochondrial
membrane and facilitate its penetration into the mitochondria [24]. Driven by the membrane potential,
the concentration of the TPP ion in the cytoplasm increases about 5–10 times compared with that in
the extracellular space, which results in an accumulation inside the mitochondria of about 100 to 500
times compared to the cytosol, thereby providing a highly effective mitochondria-targeting system [3].
The advantages of TPP-based systems for targeting mitochondria include the stability of TPP in the
biological system, the combination of lipophilic and hydrophilic moieties, low chemical reactivity
toward cellular components, and simple synthesis and purification.
Apart from TPP-based molecules, the rational design of peptides that involves the incorporation of
positive and hydrophobic building units provides efficient targeting and mitochondrial accumulation.
Szeto–Schiller (SS) peptides were early introduced as mitochondria-penetrating peptides for the
delivery of dimethyltyrosine (Dmt) as an antioxidant motif to mitochondria [25,26]. General features
of the mitochondria-penetrating peptides (MPPs) include a highly hydrophobic residue such as Fx
(cyclohexylalanine) and an alternatively placed positively charged moiety, such as arginine (R) or lysine
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(K) [27]. The high degree of delocalized positive charge and hydrophobicity enables these peptides to
easily cross the plasma membrane to specifically localize inside the mitochondria. Kelley et al. reported
that peptides with log P higher than −1.7 could easily localize inside the mitochondria carrying at
least a positive charge of +3. Certain small cationic molecules, including rhodamine, pyridinium, and
cyanine derivatives, have been shown to exhibit inherent mitochondria-penetrating ability [28,29].
These compounds are extensively used as staining agents, mitochondrial fluorescent probes, imaging
agents, and photodynamic therapy (PDT) agents as such or by conjugation with biologically relevant
compounds (Figure 1). Furthermore, there are reports describing the nanoscale delivery of anticancer
agents to the mitochondria via TPP-modified liposomes, vesicles, or dendrimers [30,31]. Since early
introduced strategies for cancer targeting are described in detail in several reviews [1,4,5,17,18],
in this review, we focus on recent strategies and progress in targeting mitochondria for cancer
therapy. Apart from the conventional approach of inducing mitochondrial damage by a cytotoxic
drug or inhibitors, drug-free approaches are introduced as potent mitochondria-targeted anticancer
therapeutics. Here, recent mitochondria-targeted therapeutics are classified into two major categories:
(1) mitochondria-targeted drug/cytotoxic agents (mito–drug conjugates) and (2) mitochondria-targeted
drug-free agents (mito-drug free agents). Motivated by the possibilities of mitochondria as a target for
cancer therapy, in this review, we discuss in detail the emerging trend in this field.
Figure 1. Chemical structure of mitochondria targeting vectors. (A) SS peptide, (B) Mitochondria
penetrating peptide (MPP), (C) TPP, pyridinium and Lipophilic Cation and (D) Indolinium based
compounds (e.g., IR-780) and Small molecules inherently localizing inside mitochondria.
2. Mito–Drug/Toxic Agent Conjugates for Cancer Therapy
Mitochondria-targeted anticancer agents were developed by conjugating mitochondria-directing
moieties, such as TPP, pyridinium, or cationic peptides, with existing anticancer drugs (doxorubicin,
camptothecin, chlorambucil, and cisplatin), mitochondrial protein/metabolism inhibitors, or other
cytotoxic agents (Figure 2). In addition, mitochondria-targeted photosensitizers have shown efficient
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induction of cell death upon light irradiation compared with cytoplasm- or lysosome-targeted analogs,
and have, therefore, attracted much attention. Thus, several photosensitizers, such as metal complexes
(Ir or Ru), IR 780, BODAPY, and indocyanine dyes, have been directed to the mitochondria and tested
for tumor curing, showing improved results compared with analogs targeted to the cytoplasm or other
organelles, especially under hypoxic condition.
Figure 2. Overview of a mitochondria-targeted drug (Mito–drug)/toxic agent for cancer therapy. In a
conventional approach, mitochondria-targeted drugs can be developed by conjugating mitochondria
targeting ligands or peptide with the toxic agents. The mitochondria-targeted toxic agents induce
mitochondrial damage by different mechanisms leading to cell death.
2.1. Conventional Drugs Targeting Mitochondria
Conventional chemotherapy drugs, including doxorubicin (DOX), Pt-based derivatives,
camptothecin, and chlorambucil, suffer from dosage limit, development of resistance, and undesirable
side effects. Their delivery to mitochondria is of pivotal importance to improve their efficacy via
different mechanisms, such as the depletion of ATP production, induction of membrane permeation,
loss of mitochondrial membrane integrity, inhibition of the mitochondrial respiratory pathway, and
damage of mitochondrial DNA case by case. Lavasanifar et al. developed TPP-conjugated DOX to
overcome drug resistance (Figure 3A) [32]. The conjugation of TPP with DOX enhanced the intracellular
accumulation capacity of the latter and afforded enhanced cytotoxicity toward both DOX-sensitive
cells and DOX-resistant cells. The TPP–DOX system was shown to preferentially accumulate in the
mitochondria of both DOX-sensitive and DOX-resistant cells. However, free DOX showed higher
cellular uptake in DOX-sensitive cells and accumulated in the nucleus. A cytotoxicity analysis in
MDA-MB-435 showed that TPP–DOX exceeded the cytotoxicity of free DOX after 72 h of incubation.
Furthermore, the resistance index (ratio of IC50 of the sample of interest to the IC50 of free DOX)
of TPP–DOX in MDA-MB-435/DOX underwent a noticeable reduction (67.7 after 72 h) compared
with that of free DOX (152 after 72 h). Meanwhile, an anticancer drug based on glycyrrhetinic acid
exhibits an inhibitory effect on cancer cell lines by inducing autophagy and activating the interaction
between CD 95 and CD 178, thereby leading to apoptosis. However, the use of glycyrrhetinic acid
is challenging because of its poor solubility and limited cellular accumulation. These issues were
solved by Wang et al. through the design of a mitochondria-targeted analog of glycyrrhetinic acid
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(Figure 3B) [33]. They developed a series of new glycyrrhetinic acid derivatives that conjugate with TPP
to specifically target the mitochondria of tumor cells. These compounds exhibited better accumulation
and selectivity toward cancer cells. Moreover, they significantly induced cell cycle arrest at the G2/M
phase, leading to the inhibition of cancer cell proliferation [33]. The mitochondria-damaging drug F16
((E)-4-(1H-Indol-3-ylvinyl)-N-methylpyridinium iodide) and DNA-damaging agent chlorambucil (CBL)
were covalently linked, resulting in the mitochondria-targeting anticancer agent Mito-Chlorambucil
(FCBL) (F 16 conjugated with CBL resulting in FCBL or mitochondria targeted CBL) (Figure 3C) [34].
FCBL accumulates in the mitochondrial matrix, damaging mtDNA, and consequently inducing
apoptosis. Recently, Mokhir et al. introduced a concept called pro-delocalized charge (pro-DLC), which
involves the activation of delocalized positive charge within the cell to generate delocalized charge
(DLC) (Figure 3D). This concept is based on theN-alkylamino ferrocene structure, in which the prodrugs
are activated by the reaction with ROS within the cell to produce DLC [35]. Since ROS are overexpressed
inside the cancer cells, higher cancer selectivity could be achieved. A conjugate of a pro-DLC agent
with the clinically approved drug carboplatin was synthesized, and its accumulation inside the cancer
cell was confirmed to be higher than that of the free drug. Moreover, a fluorescence analog of pro-DLC
accumulated inside cancer mitochondria with a Pearson coefficient of +0.8. The anticancer activity of
pro-DLCs was substantially higher than that of the parent carboplatin. Furthermore, the pro-DLC
agents exhibited a 2.7-fold increase in transmembrane potential (∆Ψc) of A2780 cells and reduced
intracellular glutathione (GSH). Generally, positively charged mitochondria-targeted ligands work
fine under in vitro conditions. In contrast, during in vivo administration, the positive charge causes
nonspecific serum protein interactions, reducing the tumor-targeting efficiency. In this regard, the
pro-DLC approach offers better selectivity for targeting cancer as the positive charge is activated only
at the site of the tumor.
Figure 3. Summary of molecular design of mitochondria-targeted conventional drugs. (A) Mitochondria-
targeted doxorubicin, (B) mitochondria-targeted glycyrrhetinic acid, (C) mitochondria-targeted
chlorambucil, and (D) mitochondria-targeted pro-DLC.
2.2. Molecules Targeting Mitochondrial Metabolism, Functions, or Proteins
Mitochondrial metabolic functions are critical for malignant cell growth; hence, targeting the
metabolic pathway is a potent strategy to inhibit cancer growth. Numerous proteins necessary for
the metabolism and energy production of mitochondria are present in their inner/outer membrane.
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The alterations of these metabolic factors affect malignant cell functions, thereby leading to cell death.
A few methods have been developed to target mitochondrial respiration or other relevant functions
that can disrupt the cancer cell mitochondria.
It is known that mitochondria are the power source of eukaryotic cells, using the oxidation of
glucose to produce ATP. ATP is generated by the transfer of electrons from nicotinamide adenine
dinucleotide (NADH) to oxygen by a series of large proteins, which occurs in the mitochondrial inner
membrane and is catalyzed by ATP synthase. Since the electron respiratory chain is related to the
capture of electrons by oxygen, it is also associated with the production of reactive singlet oxygen.
Thus, compounds that can interfere with the respiratory chain would induce oxidative stress, leading
to dysfunction of mitochondria. In this context, alpha-tocopheryl succinate (α-TOS), a vitamin E analog
that binds to the ubiquinine binding site of complex III and inhibits succinate dehydrogenase (SDH),
is used as a drug to induce the accumulation of ROS [36]. Dong et al. reported that vitamin E analogs
selectively inhibit the proliferation of diverse malignant cells [37]. In addition, α-TOS inhibits Bcl-Xl
and Bcl-2 by blocking the BH3 domain. Since higher esterase activities in normal cells compared with
the cancer cell can hydrolyze α-TOS to α-TOC (alpha-tocopherol), α-TOS exhibits reduced toxicity
toward normal cells. As another inhibitor, resveratrol inhibits complex III and decreases ROS levels.
Resveratrol is a natural antioxidant obtained from berries, and it is known to reduce oxidative stress
by inducing the expression of mitochondrial superoxide dismutase (SOD2) in mitochondria [38].
Although the effect of ROS is still undefined, resveratrol induces apoptosis through the mitochondrial
pathway, which is associated with tumor inhibition.
The maintenance of the mitochondrial membrane potential is regulated by the opening and
closing of the ion channel, mitochondrial permeability transition pore (MPTP) [39]. The abnormal
opening of MPTP induces the collapse of the mitochondrial membrane potential and release of
cytochrome c, an apoptotic factor, into the cytosol. Cancer cells have specific MPTP characteristics,
which are different from those of normal cells. One of them is the decrease in the function of the
adenine nucleotide transporter (ANT), which plays an important role in adenine exchange. Some
studies have been conducted to induce the apoptosis of cancer cells by targeting these specific traits of
MPTP [40]. Lehenkari et al. reported that clodronate, a bisphosphonate analog, can inhibit the activity
of ANT and the mitochondrial oxygen consumption, and depolarizes the mitochondrial membrane
potential [41]. The intracellular metabolism can transform clodronate into a β-γ-methylene analog
of ATP, which is a cytotoxic agent for macrophages. Although the molecular basis for the cytotoxic
effects of the clodronate metabolite AppCCl2P has not been determined yet, these authors found
that AppCCl2P inhibits adenosine triphosphate (ADP)/ATP translocation, causing apoptosis upon
long treatment. Meanwhile, Bcl proteins, which are located in the mitochondrial inner membrane,
regulate the programmed cellular death. They are overexpressed in many cancer cells, contributing
to tumor initiation progression and resistance to cancer therapy [42]. For example, expression of the
Bcl-XL protein is associated with drug resistance of cancer cells, and the reduction of Bcl-2 increases
the sensitivity to anticancer drugs. ABT-737, a small inhibitor of the antiapoptotic proteins Bcl-2,
Bcl-XL, and Bcl-W, was discovered to enhance the effects of cytotoxicity in synergy with chemo- and
radiotherapy [43]. In addition, ABT-737 was shown to disrupt the mitochondrial membrane potential,
diminish intracellular GSH, and increase ROS production.
Targeting overexpressed mitochondrial proteins in cancer cells is an alternative method to achieve
cancer selectivity. Among the hundreds of proteins present in the mitochondria, a group of proteins
known as chaperons attracts much attention due to the dependence of cancer cells on the prosurvival
functions of these proteins. A mitochondrial analog of HSP90 (a molecular chaperon), TRAP1,
is overexpressed in cancer cells, suppresses the cell death, and reorganizes the metabolic pathway.
Kang et al. reported that the major chaperon expressed in the cancer cells is TRAP 1, not HSP90. They
designed a mitochondria-targeting HSP90 inhibitor called SMTIN-P01 by conjugating TPP, which
selectively inactivates mitochondrial TRAP1 [44]. Terpyridine–platinum complexes have been reported
to inhibit thioredoxin (TrxR) effectively [45]. In this work, the rational design of TPP conjugation
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to terpyridine-Pt (TTP) provided the synergistic inhibition of both mitochondria and glycolytic
metabolism in cancer. TTP showed enhanced toxicity toward cisplatin-resistant ovarian cancer cells
and preferentially inhibited TrxR. The TEM images recorded after treating with TTP showed that
the mitochondria of Caov3 cells were severely changed to an onion-like structure with multilamellar
folding. The expression of mitofilin (IMMT), a cristae morphology regulator, was increased by TTP.
Furthermore, TTP induced autophagy and mitophagy after treatment. The membrane potential of
mitochondria was dissipated, and ATP and ROS production was lowered after treatment with TTP. TTP
inhibited both mitochondrial and glycolytic bioenergetics of cancer cell metabolism, causing cell death.
The mitochondria metabolism or protein targeted drugs, and their target of interests are summarized
in Table 1.





Target of Interest Mode of Cell Death Reference




inhibits complex III, induce the




inhibit the activity of adenine nucleotide
transporter (ANT), inhibit mitochondrial
oxygen consumption
apoptosis [40]
4 AppCCl2P ADP/ATP translocation apoptosis [40]
5 ABT-737
inhibits anti-apoptotic proteins, disturb
mitochondrial membrane potential,
increase intra cellular ROS
apoptosis [43]
6 SMTIN-P01 inhibits mitochondrial TRAP1 apoptosis [44]
7 TPP conjugatedterpyridine-Pt inhibits thioredoxin (TrxR) apoptosis [45]
2.3. Mitochondria-Targeted Peptides
Peptide drugs attract the attention of biomedical researchers due to their ease of synthesis, size
and functional group tunability, and biodegradability [46–48]. Therefore, mitochondria-targeting
agents based on peptides possess remarkable advantages over other mitochondriotropics, which
includes biocompatibility and facile synthesis. For a peptide to penetrate the mitochondrial membrane,
this peptide should be rationally designed to have optimum positive charge and hydrophobicity [27].
This could be achieved either by incorporating lipophilic cations, such as TPP (limited to short
sequence), to the peptide or by including positively charged (argininine) and hydrophobic moieties
(cyclohexyl alanine) in the peptide design, which results in a class of peptides known as MPPs [18,27].
Horton et al. developed a class of synthetic peptides that exhibit efficient cellular uptake and
specific mitochondrial localization. The latter was studied to provide an important conceptual
framework for understanding how mitochondrial localization could be achieved for synthetic
compounds. The peptides were designed to have two crucial properties, i.e., cationic charge and
lipophilicity. Previous studies of cell-penetrating peptides (e.g., TAT) indicate that the incorporation of
arginine boosts the charge-driven cellular uptake by providing cationic charge to cross the plasma
membrane, which exhibits a potential gradient that can transport cationic species by electrophoresis
from the extracellular space into the cell. The mitochondrial membrane possesses similar characteristics
with a negative potential gradient across the membrane, which facilitates the passing of the cationic
moieties through the membrane. However, the inner membrane of mitochondria is more hydrophobic
than the plasma membrane, which restricts the entry of most cell penetrating peptides (CPP) or cationic
moieties into the mitochondria. Thus, the molecules should be rationally designed to exhibit enough
hydrophobicity. Horton et al. designed a series of peptides by incorporating lysine (K) and arginine
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(R) for positive charge and phenylalanine (F) and cyclohexylalanine (Fx) for hydrophobicity. Careful
analysis revealed that compounds possessing a cationic charge of +3 or above and a log P value
of approximately −2 localized inside mitochondria, whereas below those values, compounds were
excluded from the mitochondria, instead appearing in the lysosome or nuclei [27].
MPPs can be utilized upon conjugation with a variety of cargo molecules as the transport to
mitochondria. However, the covalent conjugation of small molecules to MPPs can negatively affect
the activity of the appended cargo against the cellular target. Therefore, Kelley’s group reported
the conjugation of small molecules with MPPs using cleavable disulfide linkers for small molecule
delivery [49]. Chamberlain et al. conjugated DOX with MPPs for inhibition of DNA topoisomerase
II inside mitochondria (Figure 4A,B) [50]. This inhibition normally occurs in nuclei for conventional
DOX. However, this system exhibited reduced activity in a cell line that expresses a common efflux
pump. On the other hand, mitochondria-targeting DOX (mtDOX) provided a means to limit drug
efflux and inhibited mitochondrial DNA topoisomerase even in the efflux pump overexpressed cells.
The same group reported that mtDOX eliminates nuclear effects associated with cardiotoxicity leading
to mitochondrial biogenesis [51]. Although DOX has a high level of activity against cancer cells,
side effects, such as dose-limiting cardiotoxicity, are a bottleneck for clinical usage. This is linked to the
downstream effects of nuclear DNA damage. These authors demonstrated that mtDOX lacks any direct
nuclear effects, and can induce mitochondrial biogenesis, preventing cellular death in cardiomyocytes.
Platinum-based anticancer agents are also being developed by Kelley’s group as mitochondria-targeting
drugs [52]. Kelly’s group developed an analog of platinum conjugated with MPP for the delivery
of the anticancer drug cisplatin (mtPt) into mitochondria of cancer cells (Figure 4C,D). As a result,
mtPt induced apoptosis of cancer cells specifically without damaging nuclear DNA and mediated the
activity of platinum-based chemotherapy.
Figure 4. (A) Chemical structure of mitochondria-penetrating peptides (MPPs) conjugated with
anticancer drug cisplatin (mtPt), (B) cell cytotoxicity of mtPt in A2780 WT(wild type) and
cisplatin-resistant A2780CP70 cell for an incubation time of 72 h showing similar cytotoxicity in
both cell lines, (C) chemical structure of MPP conjugated with anticancer drug doxorubicin (mtDox),
(D) cell cytotoxicity of mtDox in A2780ADR for a treatment period of 24 h showing higher cytotoxicity
of mtDox compared with Dox. (Copyright permission received from reference [51] and [52]).
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2.4. Mitochondria-Targeted Photosensitizers
In comparison to the conventional therapeutic strategies for cancer treatment using cytotoxic
small molecular drugs, PDT offers high selectivity, no severe side effect, and rapid action [53–55].
PDT is a process consisting of two nontoxic components, a photosensitizer (PS) that acts like a drug
and a light source of a suitable wavelength, whose combination induces cancer cell death. The PSs are
localized inside the cell or subcellular compartment and are nonactive until excited by a photon of a
suitable wavelength. Upon the irradiation of light, the excited PSs transfer the energy to molecular
oxygen to generate ROS. The oxygen (O2) present in the tumor microenvironment is converted into
singlet oxygen (1O2), causing irreversible damage to the tumor tissue [56]. This process occurs only
in the particular site where the light is irradiated, and hence, PDT agents cause fewer side effects
than conventional drugs. However, there is an intrinsic barrier for the PDT to be operative in the
tumor site. The tumor microenvironment is generally hypoxic in nature, which hampers the efficient
production of toxic singlet oxygen. Inhibition of the mitochondrial respiratory pathway has been found
to increase the production of intramitochondrial oxygen, which in turn enhances the efficiency of PDT.
Thus, mitochondria-targeted PDT has attracted much attention compared with other cellular targets
or subcellular targets [57]. PDT agents can be modified with metal complexes or porphyrins having
lipophilic cations (TPP, pyridinium), cyanine, or IR-780-based PSs. Conjugation of PSs with cationic
peptides is the commonly adopted method for directing the PS inside the mitochondria of the cell.
2.4.1. Mitochondria-Targeted Metal Complexes for PDT
Lv et al. compared the efficiency of mitochondria- and lysosome-targeted iridium complexes
under hypoxic conditions. Mitochondria-targeted iridium complex Ir-P(Ph)3 (an iridium (II) complex
conjugated with triphenylphosphonium) exhibited high therapeutic efficiency compared with that of a
lysosome-targeted Ir-alkyl complex upon light irradiation. After treatment with Ir-P(Ph)3 followed
by 15 min of light irradiation (475 nm), 3.0% dead cells were detected, whereas only 0.15% dead
cells were detected upon treatment with Ir-alkyl under hypoxic condition. As expected, irradiation
under normoxia increased the percentage of dead cells compared with hypoxia conditions. This result
suggests the higher therapeutic efficiency of mitochondria-targeted Ir compounds. Under hypoxia
conditions of a tumor, where the oxygen concentration in the solid tumor is as low as 4%, the cell-killing
ability of PDT agents was much lower than the expected efficiency judging from their quantum yield
studies. The possible explanation for the high cell killing ability upon targeting mitochondria
is that the mitochondrial respiratory system might be inhibited by the PDT agents, leading to high
intramitochondrial oxygen concentration, which favors the singlet oxygen production to induce cell
death even under hypoxic conditions [58].
Among the variety of transition metal complexes, Ir-based complexes are normally selected
due to their high photostability, large stock shift, and high 1O2 quantum yield. However, due to their
hydrophobic nature, iridium complexes often aggregate inside the hydrophilic biological environment.
To address this issue, Hoe et al. designed gemini iridium (III) complexes (GIC) with adjustable water
solubility and excellent self-assembling property (vesicle structure with inhibited aggregation property),
and applied them for imaging and PDT effect [59]. To provide the Ir complexes with water solubility
and inhibit their aggregation-induced quenching, quaternary ammonium groups were conjugated with
the ligands (CN and NN) of Ir complexes. The designed GIC showed good mitochondria localization
and PDT effect both in vitro and in vivo upon light irradiation. Furthermore, the renal clearance
efficiency of GIC Ir complexes was found to improve due to their high water solubility property.
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Apart from Ir-based metal complexes, Ru complexes are widely employed for PDT studies [60].
Cationic lipophilic Ru complexes can localize inside the mitochondria. Zhou et al. reported that
integration of a chloromethyl group into the [Ru(II)(bpy)3]2+ complex localized inside the mitochondria
produces carbon radicals (type I mechanism) upon light irradiation in the presence of reductants.
NADH, abundant in mitochondria, acts as a reductant by photoinduced electron transfer from
NADH to the chloromethyl-modified Ru (II) complex. Furthermore, the scarcity of NADH disrupts
redox homeostasis and enhances apoptosis [61]. The majority of clinical and preclinical PSs, mainly
porphyrin derivatives, generate toxic ROS, singlet oxygen (1O2), via the type II mechanism (energy
transfer between PS and O2), which highly depends on the oxygen concentration. However, the
type I mechanism includes the production of superoxide anion radicals (O2−•) and hydroxyl radicals
(OH•) generated by electron transfer between the excited PS, O2, and biomolecules. Hence, type
I mechanism-based PSs deserve more attention to address hypoxia condition. Organo–ruthenium
complexes coordinated by polypyridyl ligands produce higher singlet oxygen yield as a result of their
highly populated triplet metal-to-ligand charge transfer state. Ruthenium complexes have recently
attracted much attention due to their DNA intercalation capacity and unique photophysical properties
favorable for PDT. For instance, Weil et al. presented a macromolecular approach by combining the
[Ru(bpy)3]2+ complex on a protein carrier scaffold decorated with a mitochondria-targeting moiety [62].
This approach afforded improved phototoxicity against the acute myeloid leukemia cell line, which is
an aggressive disease leading to death in up to 8 out of 10 patients. A bioinspired molecular design was
introduced, cHSA-PEO-TPP-Ru, in which the blood serum protein (HAS) acts as an efficient transporter
of PS. The complex cHSA-PEO-TPP-Ru showed an IC50 of 34.9 ± 2 nM under light irradiation, which is
the best value reported. In contrast, the control Ru complex without any modification showed an IC50
of 7.7 ± 1.3 µM. Furthermore, cHSA-PEO-TPP-Ru showed a five times higher two-photon absorption
cross section, suggesting its applicability for localized photochemical reactions beneath the skin with
minimum off-target damage.
2.4.2. Mitochondria-Targeted Small Molecules for PDT
Autofluorescence in the visible light region, lack of deep tissue penetration (near IR region), and
poor blood clearance are problems associated with PDT based on heavy metal atoms. In contrast,
small molecules, such as cyanine dye or boron-dipyrromethane (BODIPY), can overcome these issues,
since they often show good deep tissue penetration and no blood clearance issues [63]. Kim et al.
developed a mitochondria-targeting brominated near infrared NIR fluorophore (MitDt) for enhanced
PDT treatment, which allows rapid clearance and stays localized in the mitochondria for long
periods. The molecular design of MitDt consists of triphenylphosphonium (TPP) conjugation on the
heptamethine meso-position of a cyanine dye for enabling mitochondria localization, and a bromide
ion is conjugated with the indolenine group, which enhances the production of ROS by the heavy
atom effect during light irradiation with a 662 nm laser. MitDt showed no dark toxicity toward cancer
cells, but cell viability was reduced to (48.33 ± 7.39)% under light irradiation (662 nm, 100 mW cm−1,
5 min). The in vivo applicability of MitDt was evaluated in nude BALB/c mice (NCl-H460 model).
Within 1 h of injection, MitDt distributed throughout the body. When time elapsed, MitDt was
rapidly cleared from most of the organs except from the tumor, according to a biodistribution analysis.
The tumor size of the MitDt-treated group was reduced to 719.41 ± 21.20 mm3 compared with that
of the control (2499.90 ± 519.77 mm3), suggesting the high tumor-suppressing efficiency of MitDt.
The MitDt fluorophore, which stays in the tumor for a prolonged time, disrupts the mitochondria,
which results in significant tumor reduction due to ROS production during laser irradiation [64].
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Although the indocyanine dyes are promising as NIR PDT agents, their applications are limited
due to poor water solubility and dark toxicity. Thomas et al. introduced highly water-soluble
indocyanine derivatives for PDT with enhanced photostability and mitochondria-targeting ability.
The indocyanine dye IR-780 was modified with a pyridinyl group to generate the mitochondria-targeting
molecule IR-Pyr. To achieve cancer selectivity, IR-Pyr was, in turn, modified with hyaluronic acid (HA).
HA has been extensively used for selective cancer targeting due to the overexpression of HA receptors
(CD44) in cancer cells. The electrostatic interaction between positively charged CD44 and negatively
charged HA generates micellar aggregates of HA-IR-Pyr. The HA-IR-Pyr aggregates showed an IC50
of 5–7 µM in HeLa and MDA-MB 231 cell lines under PDT conditions (808 nm laser, 3 min irradiation,
200 mW), and no activity toward normal cells. In vivo administration of HA-IR-Pyr followed by
laser irradiation also showed significant tumor reduction, which renders it a good candidate for
mitochondrial-targeted PDT with high water solubility [65]. The same group developed another
powerful photodynamic therapeutic agent with a synergistic effect. They designed a conjugate of a
heat shock protein inhibitor and a PS, named as IR-PU. Since heat shock proteins are overexpressed in
cancer cells, the designed molecule IR-PU showed selective accumulation in cancer cells, possessing
an antiapoptotic property. Two relevant heat shock proteins, HSP 90 and TRAP 1, express in
both mitochondria and cytoplasm, and therefore, the rationally designed molecule IR-PU provides
simultaneous inhibition of both cytoplasmic and mitochondrial proteins. This group of proteins
acts as molecular chaperons and facilitates tumor growth and propagation. IR-PU binds with the
HSP90 protein family in the cancer cells to inhibit their chaperon activity, while mitochondria-targeted
PDT molecules rapidly damage their biological activity, thus offering a synergistic impact. Different
mitochondria-targeted conventional drugs and their advantages/disadvantages are summarized in
Table 2.
Table 2. Advantages and disadvantages of different mitochondria-targeted conventional approaches.
No. Molecular Design Advantages Disadvantages
1 Conventional drug conjugate withmitochondria targeting ligand
Enhanced cell
cytotoxicity
Induces toxicity towards normal
cell as well
2 Photosensitizer conjugate withmitochondria targeting ligand
Quick action, higher
toxicity
Induces toxicity towards normal
cell as well, requires an external
aid of laser for PS activation
3 Protein inhibitor conjugate withmitochondria targeting ligand High cancer selectivity
Induces acquired resistance as a
result of targeted protein mutation
upon repeated administration
4 Mitochondria penetrating peptideconjugate with cargo
High mitochondria
penetrating ability
Could penetrate normal cells as
well, cannot be used for higher
molecular weight cargo,
complicated design and synthesis.
3. Mitochondria-Targeted Drug-Free Agents
Clinical treatment of cancer typically involves the use of anticancer cytotoxic drugs that can kill
cancer cells by damaging or interfering with DNA. Unfortunately, this treatment system does not afford
ideal results, judging from the increasing percentage of deaths caused by cancer every year [66]. A large
number of patients do not respond to the currently available therapies and have severe side effects.
Molecular-targeted drugs based on ligand–receptor interactions, which were expected to be effective
as antitumor drugs, were introduced in the 2000s. In fact, they inhibit molecules or proteins related
to cancer cell growth and have fewer side effects than conventional chemotherapy. However, their
repeated administration causes alternation of target proteins, leading to the development of acquired
drug resistance, with the concomitant drug inactivity [67]. Therefore, it is critical to developing an
alternative strategy that could overcome the barrier imposed by conventional drugs for chemotherapy.
Research on new therapeutic systems is now focusing on the so-called “drug-free” approach. In this
approach, certain in situ macromolecular systems are introduced or formed in situ inside the cell
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or subcellular compartments to lead to cell death either by physical damage or by inhibition of the
metabolic function. Self-assembly, aggregation, polymerization, and biomineralization inside the cancer
cells are emerging examples that could tackle cancer cells efficiently [68]. In the drug-free approach,
the anticancer activity turns on once the macromolecular system interacts with the targeted cancer cell
component while being inactive in their molecular state, thus inducing fewer side effects both in vivo
and in vitro. The selective targeting of mitochondria over cytoplasm or other cellular components
attracts special attention in the drug-free approach due to properties of mitochondria, such as basic
condition, a negative membrane potential that differentiates them from normal cells, and a feasible
size of 500–1000 nm that allows a macromolecular system to be formed inside the mitochondria by
designing a proper molecular structure. Targeting mitochondria by the drug-free approach provides an
efficient way of overcoming drug resistance by decreasing the drug efflux by forming a supramolecular
system inside the mitochondria, leading to cell death via different mechanisms including depletion
of ATP production, which is primary for cell survival, loss of membrane integrity, and release of
cytochrome C and apoptotic proteins. Since most of the mitochondria system does not rely on a specific
target protein, the possibility to develop acquired resistance during the clinical administration is lower,
thus offering an efficient anticancer strategy. Intramitochondrial aggregation, intramitochondrial
self-assembly, and intramitochondrial biomineralization are mitochondria-targeted drug-free strategies,
which are discussed below (Figure 5).
Figure 5. Overview of a mitochondria-targeted drug-free approach. In this approach, the monomer is
designed with the ability to either polymerize, self-assemble, or aggregate inside the cancer mitochondria
taking advantage of cancer mitochondria characteristics such as higher negative membrane potential,
higher basicity inside the matrix or overproduction of ROS. The resulting supramolecular system leads
to mitochondria damage, causing cell death.
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3.1. Aggregation of Rationally Designed Molecules Inside the Mitochondria
An aggregating molecule with aggregation-induced emission (AIE) property in mitochondria was
introduced by Liu et al. The higher negative membrane potential of cancer mitochondria (about 60 mV
over their normal counterparts) increases the accumulation of the designed molecule AIE-mito-TPP
in cancer mitochondria compared with normal mitochondria, providing high selectivity (Figure 6A).
This molecule serves as a light-up probe for image-guided therapy by conjugating TPP with a fluorogen,
which can undergo AIE. The probe AIE-mito-TPP enters the target mitochondria and self-aggregates
to emit fluorescence. AIE-mito-TPP induces cancer cell death as a result of membrane damage, ROS
generation, and ATP depletion. In contrast, normal cells remain unaffected under similar treatment
conditions [69]. Meanwhile, Kim et al. developed a biomineralization approach inside mitochondria for
inducing apoptosis of cancer cells. Biomineralization, the process by which a living organism produces
minerals, is an essential process for the generation of bio objects such as bones and teeth. Cellular
functions are also regulated by isolation and secretion of intracellular mineral deposits. Although the
potential use of extracellular biomineralization was recently reported, abnormal mineral deposits could
inflict damage to normal cells near the nucleation sites. To overcome this drawback, the combination
of an intracellular targeting strategy with biomineralization could offer new theranostics with reduced
side effects. A mitochondria-targeting biomineralization system was introduced by conjugating TPP
into trialkoxysilane. The trialkoxysilane group undergoes an environment-responsive silicification
process inside the slightly basic mitochondrial matrix (~pH 8) (Figure 6B). This biomineralization
exhibits concentration-dependent property. In cancer cells, the building blocks can accumulate into
mitochondria above critical concentration, but not in normal cells because of the TPP-driven targeting
ability. The accumulated condition and mitochondrial basic environment provide the appropriate
condition that favors biomineralization inside cancer mitochondria. The resulted biominerals induce
mitochondrial stress, leading to dysfunction of mitochondria and activation of apoptotic pathways.
The cell viability analysis of the mitochondria-targeted biomineralizing compound showed an IC50 of
10–20 µM in varies cancer cell lines, such as HeLa, MDA-MB-231, SCC7, PC3, and KB, which contrasts
with the low toxicity exhibited by normal cells [70]. Both approaches showed less damage to normal
cells, which is a major advantage of targeting cancer mitochondria by the drug-free approach.
Figure 6. Figure showing (A) intramitochondrial aggregation with a rationally designed probe
AIE-mito-TPP, that aggregate inside cancer cell mitochondria driven by higher negative membrane potential
and undergoes aggregation-induced emission, later leading to apoptosis and (B) intramitochondrial
biomineralization of silane containing compounds that polymerize inside the mitochondria driven by
the higher accumulation and slightly basic pH (~8) of the mitochondrial matrix. (Copyright permission
received from [69] and we thank RSC for figure 6B from [70]).
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3.2. In Situ Nanostructures Inside Mitochondria for Cancer Therapy
Mitochondria-targeted self-assembled peptides were developed by Wang et al. for multitargeting,
high selectivity, and minimal drug resistance. The same group established enzyme-instructed
self-assembly (EISA) as an alternative strategy for cancer therapy, which is a pioneering example
of a drug-free approach for cancer therapy. In this approach, a peptide bearing enzyme-sensitive
hydrophobic building unit transforms into a hydrophobic self-assembling unit via an enzyme–substrate
reaction. The highly hydrophobic self-assembling peptides undergo self-assembly in the pericellular
space, cell membrane, or inside the cell, leading to apoptosis [71]. To achieve mitochondria-targeted
EISA for cancer therapy, the self-assembling peptide NBD-FFYpK-TPP was synthesized bearing
4-nitro-2,1,3-benzoxadiazole (NBD) as a fluorophore, FFYK (phe-phe-tyr-lys)as a self-assembling
peptide unit, tyrosine phosphate (Yp) as an ALP (alkaline phosphatase) enzymatic substrate, and
TPP as a mitochondria-targeting unit. The hydrophilic peptide turns to hydrophobic with high
self-assembling propensity near the cell membrane due to the dephosphorylation of Yp by the
action of ALP, which is expressed in the cell membrane. The peptide self-assembles into nanofibers
and is internalized into target mitochondria via endocytosis. The nanofibers induce cell death by
initiating an intrinsic apoptotic cascade [72]. The repeated stimulation of ALP overexpressed cells by
NBD-FFYpK-TPP showed similar cytotoxicity to that of the unstimulated cells, suggesting the lack of
acquired resistance to the cells.
One concern about pericellular self-assembly is that the peptide requires a high concentration
in the range of several hundred micromolar (µM) to millimolar (mM) to self-assemble inside the
cell or pericellular space, and the enzymatic expression varies from cell to cell, which hampers its
application as a therapeutic agent. This issue was addressed by Jeena et al. by introducing mitochondria
localization-induced self-assembly for cancer therapy (Figure 7). In their work, the targeted amphiphilic
peptide self-assembles inside the mitochondria to form nanofibers. The intramitochondrial self-assembly
of the designed peptide was induced by the high local concentration inside the confined space. The size
of mitochondria is very small, ranging from 0.5 µm to 1 µm, compared to the size of the whole cell
(~15–20 µm). As a result, inside the mitochondria, the peptide experiences a 100–500-fold increment
in concentration. The Py-FFK-TPP (Mito-FF) peptide was synthesized as a model peptide. Pyrene
butyric acid (Py) was conjugated for the fluorescent detection inside the cell and TPP for mitochondria
targeting. The peptide formed fibers of 10 nm in diameter under physiological conditions. A cellular
incubation showed that the peptide localized inside the mitochondria, raising its concentration to
2.6 mM for an incubation concentration of 10 µM, which induced rapid self-assembly into nanofibers
inside the mitochondria. The self-assembled fibers disrupted the mitochondria membrane to induce
apoptosis. This approach constitutes an alternative strategy to overcome challenges imposed on
cancer therapy, such as drug resistance and solubility issues [73]. Furthermore, the coincubation of
both L and D isomers, i.e., Mito-FF and Mito-ff in 1:1 ratio (racemic mixture, Mito-rac) induced the
formation of superstructures inside the mitochondria as a result of their heterochiral coassembly [74].
The superstructured fibrils induced selective damage of cancer mitochondria much more efficiently
than the enantiomeric analog both in vitro and in vivo, resulting in enhanced cytotoxicity and tumor
inhibition capability. The enhanced cellular damage of Mito-rac is caused by the higher area and depth of
mitochondrial membrane penetration by the superstructured fibrils of 30–100 nm in diameter and several
micrometers in length. Several reports describe that the heterochiral self-assembly of peptides produces
nanostructures with enhanced mechanical property and enzymatic stability. However, this is the first
report showing heterochiral self-assembly in the cellular environment for therapeutics and offers a new
approach for tuning the biological activity of peptides by combining D and L isomers in different ratios.
In both systems, cell death was induced by destroying mitochondrial membrane integrity. The fibers
formed in situ interact with the mitochondrial membrane and induce the formation of pores by vertically
penetrating the mitochondrial membrane, causing the release of apoptotic bodies that leads to cell death.
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Figure 7. (A) Schematic illustration of mitochondria localization induced self-assembly of peptide
amphiphiles. The peptides accumulate inside the mitochondria, exceed the critical aggregation
concentration (CAC), and result in the formation of nanofibers. The nanofiber interacts with the
mitochondrial membrane, induces the release of proteins, apoptotic factors leading to apoptosis of the
cell, (B) TEM image of nanofiber inside the mitochondria, (C) release of proteins from the mitochondria to
the cytosol after treating with an intra-mitochondrially self-assembling peptide.(Copyright permission
received from [73]).
Small molecule-based anticancer agents are usually rapidly cleared from the body, reducing targeting
efficiency. However, nano assemblies, such as nanoparticle-based therapy, offer high circulation and
tumor targeting by the EPR effect. Wang et al. constructed a polymer–peptide conjugate consisting of
a β-sheet-forming peptide (KLVFF), a mitochondria-targeting peptide (KLAK), and polyvinyl alcohol
(PVA) as a backbone. The designed nanomaterial forms nanoparticles under physiological conditions
that are responsive toward ROS, transforming into nanofibers near the mitochondria. This morphology
transformation is triggered by a change in the hydrophobic–hydrophilic balance. The polymer–peptide
complex showed high mitochondrial disruption ability against HeLa cells, with an IC50 value of about
10 µg/mL, much lower than that of free KLAK and other controls. The morphology transformation
is operative under in vivo conditions. In the in vivo system, a Cy5-labeled complex was shown to
accumulate at the tumor site and reach the highest intensity in 24 h [75]. He et al. reported a
branched peptide targeting mitochondria that carries a negative charge. A self-assembling motif
conjugated with a protein tag (FLAG-tag) forms micelles. The protein tag FLAG (DDDDK) is cleaved
by the enzyme entarokinase (ENTK), which transforms micelle to nanofibers. This transformation
occurs in the intracellular environment, and the as-formed nanofibers are located in the mitochondria.
The FLAG-tag precursor delivers cargo to the mitochondria, as evidenced by the delivery of DOX or RPE
(R-phycoerythrin). The branched peptide precursor decreases the IC50 of DOX from 3.0 to 400 nM [76].
4. Conclusions and Future Outlook
Hundreds of strategies to achieve cancer-selective mitochondrial damage leading to apoptosis have
been introduced so far. The conventional strategies of targeting mitochondria for cancer therapy include
mitochondria-targeted cytotoxic drugs, mitochondrial protein inhibitors, and mitochondria-localized
PDT, offering excellent cancer mitochondria-targeting/damaging efficiency. The modern strategy
of targeting mitochondria in drug-free approaches promises advantages, such as lack of acquired
resistance, higher selectivity, and lower working concentration. Generally, drug-free approaches do not
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rely on a specific protein target inside mitochondria but damage its structural or functional features,
which render such approaches less prone to acquire drug resistance. Table 3 summarizes the barriers
and advantages of different mitochondria-targeted drugs towards the clinical trial.
Table 3. Analysis of the possibility of different mitochondria-targeted molecules to be available for the
practical application.
No. Molecular Design Barrier for PracticalApplication
Advantages for Practical
Application
1 Conventional drug conjugate withmitochondria targeting ligand Fetal toxicity and side effects -
2 Protein inhibitor conjugate withmitochondria targeting ligand
Complicated synthetic
procedure, acquired resistance High tumor selectivity
3 Mitochondria penetrating peptideconjugate with cargo
Complicated molecular design,
needs to carry a cargo. -
4 Mitochondria-targeted drug-freeagents -
Work at small concertation, ease of
production, high selectivity towards
the tumor, fewer side effects.
However, certain challenges still need to be overcome for the ideal performance of the drug-free
strategy. First, for a molecule to penetrate the mitochondrial membrane, it requires positive charge and
lipophilicity, which often results in molecular uptake by normal cells as well. Second, the presence of
a positive charge in the mitochondria-targeting compounds limits their applicability under in vivo
conditions, since the negatively charged enzymes or proteins could interact with mitochondriotropic
agents, reducing the targeting efficiency. To improve the performance of the drug-free approaches,
the mitochondria localization-induced self-assembly of the amphiphilic peptide can be envisaged as a
powerful strategy; however, drawbacks such as the fast clearance of small molecules from the body
during in vivo administration, poor selectivity, and nonspecific interaction of positive charges hinder
its applicability. To overcome this issue, the mitochondria localization-induced self-assembly could be
integrated with stimuli responsiveness, such as enzyme or pH for enhancing the targeting efficiency, and
the construction of nanostructures with intra-mitochondrially assembling molecules could circumvent
the problems of blood clearance and off-target effect. This combination of stimuli responsiveness
or nanostructure with the desired mitochondria-targeted drug-free strategy greatly enhances the
performance. In the future, further research on the design and development of mitochondria-targeted
drug-free compounds or strategies is highly expected to result in clinical trials for efficient and
side-effect-free cancer therapeutics.
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